|
⚲
|
| Keyboard |
| Fairmount Funds Management LLC
✚
|
|
|---|---|
| CRD # | 284844 |
| SEC # | 801-116848 |
| CIK # | 0001802528 |
| AUM | 5,799.1 M (2026-03-31) |
| Employees | 30 (40% Investors, 0% Brokers) |
| Phone | 267-262-5300 |
| Address | 200 Barr Harbor Drive West Conshohocken, PA 19428 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Galecto Inc | 225.7 | ||
| Magenta Therapeutics Inc | 212.9 | ||
| UNUM Therapeutics Inc | 211.8 | ||
| Aeglea Biotherapeutics Inc | 202.7 | ||
| ARCA Biopharma Inc | 181.7 | ||
| Signal Genetics Inc | 76.6 | ||
| Imara Inc | 72.7 | ||
| Aerovate Therapeutics Inc | 64.0 | ||
| Glycomimetics Inc | 50.5 | ||
| Zenas Biopharma Inc | 46.1 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Fairmount Healthcare Co-Invest V LP | [2026-02-10] | 80.3 M | |
| Filed 2025-11-05 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1 · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| PE | Fairmount Healthcare Co-Invest IV LP | [2025-02-20] | 41.6 M | |
| Filed 2024-10-31 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1 · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| PE | Fairmount Healthcare Co-Invest III LP | [2024-08-15] | 78.6 M | |
| Filed 2024-03-29 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1 · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| PE | Fairmount Healthcare Co-Invest II LP | [2023-11-15] | 15.2 M | 24.9 M |
| Offered $15,173,000 · Filed 2023-08-21 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1 · Duration One year or less · Net Assets Decline to Disclose | ||||
| PE | Fairmount Healthcare Co-Invest LP | [2023-08-18] | 25.0 M | 38.7 M |
| Offered $25,000,000 · Filed 2023-06-30 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1 · Duration One year or less · Net Assets Decline to Disclose | ||||
| PE | Fairmount SPV I LLC | 2022-03-31 | 1.6 M | |
| PE | Fairmount SPV III LLC | 2020-04-17 | 0.6 M | |
| HF | Fairmount Healthcare Fund II LP | [2019-05-24] | 28.0 M | 5,598.6 M |
| Filed 2020-10-27 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Fairmount SPV II LLC | 2019-05-24 | 0.4 M | |
| HF | Fairmount Healthcare Fund LP | [2018-02-13] | 3.6 M | 111.0 M |
| Filed 2020-10-27 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 4 | 5.8 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 4 | 5.8 |
| By Discretionary | ||
| Discretionary | 4 | 5.8 |
| Non-Discretionary | 0 | 0.0 |
| Total | 4 | 5.8 |
| By Non-United States Persons | ||
| Non-United States Persons | 2.8 | |
| United States Persons | 3.0 | |
| Total | 4 | 5.8 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Tomas Kiselak | Executive Officer | 25 | 2 | |
| Peter Harwin | Executive Officer | 22 | 2 | |
| Fairmount Funds Management LLC | Executive Officer | 8 | 2 | |
| Investment Manager Fairmount Funds Management LLC | Promoter | 2 | 1 | |
| General Partner Fairmount Healthcare Fund GP LLC | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001802528] | |
| 3 | [0001802528] | |
| 4 | [0001802528] | |
| SC 13D | [0001802528] | |
| SC 13G | [0001802528] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 549300KMPFHUFJ6T6Y84 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Cogent Biosciences Inc COGT
Common Stock
|
2026-03-31 | Conversion | 7,000,000 | ||
|
Cogent Biosciences Inc COGT
Common Stock
|
2026-03-31 | Sell | 7,000,000 | $34.66 | 242,620,000 |
|
Cogent Biosciences Inc COGT
Series A Convertible Preferred Stock · derivative
|
2026-03-31 | Conversion | 28,000 | $0.00 | |
|
Damora Therapeutics Inc DMRA
Stock Option (right to buy) · derivative
|
2026-03-23 | Grant | 37,313 | $0.00 | |
|
Damora Therapeutics Inc GLTO
Common Stock
|
2026-02-09 | Option exercise | 5,809,000 | $0.00 | |
|
Damora Therapeutics Inc GLTO
Series C Preferred Stock · derivative
|
2026-02-09 | Option exercise | 5,809 | $0.00 | |
|
Damora Therapeutics Inc GLTO
Series C Preferred Stock · derivative
|
2026-02-09 | Option exercise | 2,904 | $0.00 | |
|
Damora Therapeutics Inc GLTO
Common Stock
|
2026-02-09 | Option exercise | 2,904,000 | $0.00 | |
|
Apogee Therapeutics Inc APGE
Common Stock
|
2026-01-22 | Sell | 1,750,000 | $76.30 | 133,525,000 |
|
Cogent Biosciences Inc COGT
Common Stock
|
2026-01-22 | Sell | 3,500,000 | $36.40 | 127,400,000 |
|
Crescent Biopharma Inc CBIO
Ordinary Shares
|
2025-12-04 | Buy | 1,360,000 | $13.41 | 18,237,600 |
|
Crescent Biopharma Inc CBIO
Pre-Funded Warrant (Right to Buy) · derivative
|
2025-12-04 | Buy | 131,434 | $13.41 | 1,762,530 |
|
Miragen Therapeutics Inc VRDN
Common Stock
|
2025-10-23 | Buy | 454,545 | $22.00 | 9,999,990 |
|
Zenas BioPharma Inc ZBIO
Common Stock
|
2025-10-07 | Buy | 316,219 | $19.00 | 6,008,161 |
|
Jade Biosciences Inc JBIO
Pre-Funded Warrant (Right to Buy) · derivative
|
2025-10-06 | Grant | 855,047 | $9.14 | 7,815,130 |
|
Jade Biosciences Inc JBIO
Common Stock
|
2025-10-06 | Grant | 1,333,126 | $9.14 | 12,184,772 |
|
Cogent Biosciences Inc COGT
Common Stock
|
2025-07-10 | Buy | 2,777,777 | $9.00 | 24,999,993 |
|
Crescent Biopharma Inc CBIO
Stock Option (Right to Buy) · derivative
|
2025-06-23 | Grant | 9,023 | $0.00 | |
|
Apogee Therapeutics Inc APGE
Stock Option (Right to Buy) · derivative
|
2025-06-17 | Grant | 14,461 | $0.00 | |
|
Apogee Therapeutics Inc APGE
Stock Option (Right to Buy) · derivative
|
2025-06-17 | Grant | 14,461 | $0.00 | |
| showing 20 of 110 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
PennantPark Investment Advisers LLC
✚
|
FL | 6,155.9 M |
|
Polen Capital Credit LLC
✚
|
MA | 6,129.5 M |
|
JC Flowers & Co LLC
✚
|
NY | 6,010.1 M |
|
HG VORA Capital Management LLC
✚
|
NY | 5,872.6 M |
|
Torchlight Investors LLC
✚
|
NY | 5,843.9 M |
|
Sun Capital Advisors LP
✚
|
FL | 5,843.3 M |
|
Axium Infrastructure US Inc
✚
|
NY | 5,830.4 M |
|
Saluda Grade Asset Management LLC
✚
|
NY | 5,826.7 M |
|
Dynamic Beta Investments LLC
✚
|
CT | 5,674.3 M |
|
Lime Rock Management LP
✚
|
CT | 5,478.5 M |